Literature DB >> 25849507

Structure of the ABL2/ARG kinase in complex with dasatinib.

Byung Hak Ha1, Mark Adam Simpson1, Anthony J Koleske1, Titus J Boggon1.   

Abstract

ABL2/ARG (ABL-related gene) belongs to the ABL (Abelson tyrosine-protein kinase) family of tyrosine kinases. ARG plays important roles in cell morphogenesis, motility, growth and survival, and many of these biological roles overlap with the cellular functions of the ABL kinase. Chronic myeloid leukemia (CML) is associated with constitutive ABL kinase activation resulting from fusion between parts of the breakpoint cluster region (BCR) and ABL1 genes. Similarly, fusion of the ETV6 (Tel) and ARG genes drives some forms of T-cell acute lymphoblastic leukemia (T-ALL) and acute myeloid leukemia (AML). Dasatinib is a tyrosine kinase inhibitor used for the treatment of CML by inhibiting ABL, and while it also inhibits ARG, there is currently no structure of ARG in complex with dasatinib. Here, the co-crystal structure of the mouse ARG catalytic domain with dasatinib at 2.5 Å resolution is reported. Dasatinib-bound ARG is found in the DFG-in conformation although it is nonphosphorylated on the activation-loop tyrosine. In this structure the glycine-rich P-loop is found in a relatively open conformation compared with other known ABL family-inhibitor complex structures.

Entities:  

Keywords:  ABL2; ARG

Mesh:

Substances:

Year:  2015        PMID: 25849507      PMCID: PMC4388181          DOI: 10.1107/S2053230X15004793

Source DB:  PubMed          Journal:  Acta Crystallogr F Struct Biol Commun        ISSN: 2053-230X            Impact factor:   1.056


  31 in total

1.  An EGFR-Src-Arg-cortactin pathway mediates functional maturation of invadopodia and breast cancer cell invasion.

Authors:  Christopher C Mader; Matthew Oser; Marco A O Magalhaes; Jose Javier Bravo-Cordero; John Condeelis; Anthony J Koleske; Hava Gil-Henn
Journal:  Cancer Res       Date:  2011-01-21       Impact factor: 12.701

Review 2.  ABL tyrosine kinases: evolution of function, regulation, and specificity.

Authors:  John Colicelli
Journal:  Sci Signal       Date:  2010-09-14       Impact factor: 8.192

3.  Integrin-mediated dendrite branch maintenance requires Abelson (Abl) family kinases.

Authors:  Eva Marie Yang Moresco; Stephanie Donaldson; Anne Williamson; Anthony J Koleske
Journal:  J Neurosci       Date:  2005-06-29       Impact factor: 6.167

4.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

5.  Essential roles for the Abl and Arg tyrosine kinases in neurulation.

Authors:  A J Koleske; A M Gifford; M L Scott; M Nee; R T Bronson; K A Miczek; D Baltimore
Journal:  Neuron       Date:  1998-12       Impact factor: 17.173

6.  The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene.

Authors:  Y Ben-Neriah; G Q Daley; A M Mes-Masson; O N Witte; D Baltimore
Journal:  Science       Date:  1986-07-11       Impact factor: 47.728

7.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.

Authors:  B J Druker; S Tamura; E Buchdunger; S Ohno; G M Segal; S Fanning; J Zimmermann; N B Lydon
Journal:  Nat Med       Date:  1996-05       Impact factor: 53.440

8.  REFMAC5 for the refinement of macromolecular crystal structures.

Authors:  Garib N Murshudov; Pavol Skubák; Andrey A Lebedev; Navraj S Pannu; Roberto A Steiner; Robert A Nicholls; Martyn D Winn; Fei Long; Alexei A Vagin
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-03-18

9.  Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class.

Authors:  Eidarus Salah; Emilie Ugochukwu; Alastair J Barr; Frank von Delft; Stefan Knapp; Jonathan M Elkins
Journal:  J Med Chem       Date:  2011-03-18       Impact factor: 7.446

10.  MolProbity: all-atom structure validation for macromolecular crystallography.

Authors:  Vincent B Chen; W Bryan Arendall; Jeffrey J Headd; Daniel A Keedy; Robert M Immormino; Gary J Kapral; Laura W Murray; Jane S Richardson; David C Richardson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-12-21
View more
  3 in total

1.  Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance.

Authors:  Theresa Klümper; Henrike Bruckmueller; Tobias Diewock; Meike Kaehler; Sierk Haenisch; Christiane Pott; Oliver Bruhn; Ingolf Cascorbi
Journal:  Exp Hematol Oncol       Date:  2020-09-26

2.  Molecular dynamics simulations of the conformational plasticity in the active pocket of salt-inducible kinase 2 (SIK2) multi-state binding with bosutinib.

Authors:  Mingsong Shi; Lun Wang; Kongjun Liu; Yong Chen; Mengshi Hu; Linyu Yang; Jun He; Lijuan Chen; Dingguo Xu
Journal:  Comput Struct Biotechnol J       Date:  2022-05-23       Impact factor: 6.155

3.  Dasatinib-SIK2 Binding Elucidated by Homology Modeling, Molecular Docking, and Dynamics Simulations.

Authors:  Mingsong Shi; Lun Wang; Penghui Li; Jiang Liu; Lijuan Chen; Dingguo Xu
Journal:  ACS Omega       Date:  2021-04-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.